WTA Mandates Gene Test for Women's Tennis Eligibility

The Women's Tennis Association (WTA) has implemented a new eligibility requirement mandating that all female players undergo a one-time gene test. This test is designed to identify the presence of the SRY gene, which is a key determinant of biological sex. The new policy aims to standardize eligibility criteria within professional women's tennis.

The SRY gene, located on the Y chromosome, plays a crucial role in the development of male reproductive organs. Its presence or absence is a primary biological indicator used in sex determination. The WTA's decision to incorporate genetic testing reflects a broader ongoing discussion and evolving regulations in sports regarding the inclusion of transgender athletes and the definition of sex-based categories.

This policy change comes at a time when various sports organizations globally are reviewing and updating their rules concerning gender eligibility. The WTA's approach focuses on a specific genetic marker to establish a biological baseline for participation in the women's category. Further details on the implementation and the specific protocols for administering the test are expected to be released by the association.